Comparison of weekly and 3-weekly schedule of docetaxel as second line treatment of advanced non-small-cell lung cancer (NSCLC): A meta-analysis of individual data from 818 patients

被引：0
|
作者：
Di Maio, M.
Perrone, F.
Chiodini, P.
Gallo, C.
Camps, C.
Quoix, E.
Schuette, W.
Gridelli, C.
机构：
[1] Ist Nazl Tumori, Unita Sperimentaz Clin, Naples, Italy
[2] Seconda Univ Napoli, Dipartimento Med Pubbl Clin & Prevent, Naples, Italy
[3] Hosp Gen Univ, Valencia, Spain
[4] Hop Lyautey, Strasbourg, France
[5] Martha Maria City Hosp Halle Doelau, Halle, Germany
[6] Azienda Osped S Giuseppe Moscati, Avellino, Italy
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：XI25 / XI25
页数：1
相关论文
共 50 条
  • [21] Weekly chemotherapy of cisplatin and docetaxel for elderly patients with non-small-cell lung cancer
    Ohe, Y
    Niho, S
    Minami, H
    Saijo, N
    Watanabe, K
    Yokoyama, A
    Nishiwaki, Y
    LUNG CANCER, 2004, 45 : S76 - S77
  • [22] Phase II study of weekly docetaxel combined with cisplatin in patients with advanced non-small-cell lung cancer
    Tsunoda, T
    Koizumi, T
    Hayasaka, M
    Hirai, K
    Koyama, S
    Takabayashi, Y
    Fujimoto, K
    Kubo, K
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2004, 54 (02) : 173 - 177
  • [23] Phase II study of weekly docetaxel combined with cisplatin in patients with advanced non-small-cell lung cancer
    Toshiyuki Tsunoda
    Tomonobu Koizumi
    Muneharu Hayasaka
    Kazuya Hirai
    Shigeru Koyama
    Yasuki Takabayashi
    Keisaku Fujimoto
    Keishi Kubo
    Cancer Chemotherapy and Pharmacology, 2004, 54 : 173 - 177
  • [24] Weekly administration of gemcitabine plus docetaxel in advanced non-small cell lung cancer (NSCLC).
    Sun, Y
    Li, J
    Wu, Y
    Li, L
    Gu, L
    Zhang, L
    Wang, J
    Zhang, X
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 698S - 698S
  • [25] Weekly treatment of non-small-cell lung (NSCLC) cancer patients with paclitaxel (P) and carboplatin (C)
    Schroeder, M
    Ukena, D
    Schutte, W
    Schroder, R
    Westerhausen, M
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 1064 - 1064
  • [26] WEEKLY DOCETAXEL (TXT) WITH WEEKLY GEMCITABINE AS PROLONGED INFUSION (GEM) IN PATIENTS WITH ADVANCED, PRETREATED NON-SMALL-CELL LUNG CANCER (NSCLC): PRELIMINARY REPORT OF A PHASE II STUDY
    Antonelli, Giovanna
    Priolo, Domenico
    Amadio, Placido
    Colina, Paolo
    Vitale, Felice
    Ferrau, Francesco
    ANNALS OF ONCOLOGY, 2004, 15 : 31 - 31
  • [27] Phase II trial of a combination of weekly docetaxel and four-weekly carboplatin in the first-line treatment of advanced non-small cell lung cancer (NSCLC)
    Ozguroglu, Mustafa
    Evrensel, Turkkan
    Er, Ozlem
    Turna, Hande
    Yanmaz, Teoman
    Yildiz, Ozcan
    Mandel, Nil
    Serdengecti, Suheyla
    ANNALS OF ONCOLOGY, 2006, 17 : 225 - 225
  • [28] Single agent vs combination chemotherapy (CT) as second-line treatment of advanced non-small-cell lung cancer (NSCLC): Individual patients data meta-analysis of five randomized trials
    Di Maio, M.
    Chiodini, P.
    Georgoulias, V.
    Hatzidaki, D.
    Takeda, K.
    Wachters, F. M.
    Gebbia, V.
    Morabto, A.
    Perrone, F.
    Gridelli, C.
    ANNALS OF ONCOLOGY, 2008, 19 : 139 - 139
  • [29] Second-line chemotherapy for non-small-cell lung cancer with monthly docetaxel and weekly gemcitabine: A phase II trial
    Spiridonidis, CH
    Laufman, LR
    Carman, L
    Moore, T
    Blair, S
    Jones, J
    George, C
    Patel, T
    Roach, R
    Rupert, R
    Zangmeister, J
    Colborn, D
    Kuebler, JP
    ANNALS OF ONCOLOGY, 2001, 12 (01) : 89 - 94
  • [30] Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer: a network meta-analysis
    Popat, Sanjay
    Mellemgaard, Anders
    Fahrbach, Kyle
    Martin, Alison
    Rizzo, Maria
    Kaiser, Rolf
    Griebsch, Ingolf
    Reck, Martin
    FUTURE ONCOLOGY, 2015, 11 (03) : 409 - 420
12345